证券代码：603456 证券简称：九洲药业 公告编号：2025-012 浙江九洲药业股份有限公司 关于 2024 年年度利润分配预案及 2025 年中期分红 授权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配金额：每 10 股派发现金红利 3.00 元（含税）。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日 期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股分 配比例不变，相应调整分配总额，并将另行公告具体调整情况。 本期利润分配不会导致公司触及《上海证券交易所股票上市规则》第 9.8.1 条第一款第（八）项规定的可能被实施其他风险警示的情形。 一、利润分配方案内容 （一）利润分配方案的具体内容 截至 2024 年 12 月 31 日，公司母公司报表中期末未分配利润为人民币 679,137,433.29 元。经董事会决议，公司 2024 年年度拟以实施权益分派股权登记 日登记的总股本为基数分配利润。本次利润分配方案如下： 公司拟向全体 ...

Profit Distribution and Financial Performance - The profit distribution plan for 2024 proposes a cash dividend of 3.00 CNY per 10 shares (tax included) to all shareholders, with no capital increase or bonus shares issued this year[4]. - The company's operating revenue for 2024 was CNY 5,160,584,725.38, a decrease of 6.57% compared to CNY 5,523,418,175.43 in 2023[22]. - The net profit attributable to shareholders for 2024 was CNY 606,096,350.90, down 41.34% from CNY 1,033,255,687.14 in 2023[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 593,522,422.32, a decrease of 42.06% compared to CNY 1,024,292,645.51 in 2023[22]. - The net cash flow from operating activities for 2024 was CNY 991,655,174.07, down 27.10% from CNY 1,360,323,930.39 in 2023[22]. - The total cash dividend amount has been adjusted to 445,387,214 RMB, based on a share capital of 890,774,428 shares, following the repurchase of 8,660,800 shares[186]. - The cumulative cash dividend amount over the last three accounting years is 1,069,795,943.60 RMB, with a cash dividend ratio of 137.06% based on the average net profit of 853,507,469.54 RMB[190]. Audit and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm, ensuring the accuracy and completeness of the financial report[3]. - There are no non-operating fund occupations by controlling shareholders or related parties, and no violations in decision-making procedures for external guarantees[6]. - The board of directors and supervisory board members have all attended the board meeting, ensuring accountability for the report's content[3]. - The report includes a comprehensive overview of the company's governance and social responsibility initiatives[8]. - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute commitments to investors, highlighting investment risks[5]. - The audit committee's report indicated that the financial statements are free from significant errors or omissions, enhancing the reliability of the financial data presented[173]. Risk Management and Challenges - The company has detailed potential risks in the report, which can be found in the "Management Discussion and Analysis" section[6]. - The company faces risks related to the lifecycle changes of innovative drugs and potential market competition, which could impact sales and profit margins[144][147]. - The company is exposed to regulatory risks due to the high level of scrutiny in the pharmaceutical industry, which may affect its operations if it fails to adapt to changing regulations[146]. - The company has established a flexible pricing mechanism to mitigate foreign exchange risks associated with its significant overseas business[150]. Research and Development - The company has established multiple core technology platforms, including continuous flow technology, chiral catalysis, fluorochemistry, and biocatalysis, enhancing its R&D capabilities[34][35][36]. - The chiral catalysis platform delivered 80 chiral ligands and developed a new small molecule catalytic reaction system, applying for 7 patents in 2024[34]. - The biocatalysis platform expanded its enzyme library by developing over 180 types of enzymes and applied for 4 new patents in 2024[36]. - The formulation technology platform has nearly 100 projects under research and has applied for 49 patents, with 29 already authorized[41]. - The company has built a rich enzyme library and developed high-performance enzyme catalysts, successfully scaling up production for over 40 enzyme-catalyzed synthesis processes[64]. - The company has developed non-natural amino acid synthesis technology and established a library for innovative drug development, aiming to reduce production costs and enhance competitiveness[67]. Market and Business Strategy - The company is actively expanding its CDMO business layout and deepening partnerships to support long-term development[33]. - The global pharmaceutical market is projected to reach $2.3 trillion by 2028, with a compound annual growth rate (CAGR) of approximately 5-8% from 2023 to 2028[54]. - The global CDMO market reached $63.2 billion in 2021, with an expected CAGR of 18.5%, projected to reach $124.3 billion by 2025, outpacing the growth of the global drug market[55]. - The company aims to enhance its small molecule CDMO service capabilities by 2025, focusing on optimizing operational efficiency and expanding customer relationships[135]. - The company plans to strengthen its overseas business and R&D teams, attracting high-level talent to enhance its service offerings[135]. Corporate Governance - The company held 3 shareholder meetings during the reporting period, ensuring compliance with legal requirements and protecting the rights of all shareholders, especially minority shareholders[153]. - The board of directors consists of 9 members, including 3 independent directors, and has established four specialized committees to enhance decision-making and oversight[154]. - The company has implemented a strict insider information management system to ensure fair and transparent information disclosure during significant events[156]. - The company has a remuneration and assessment committee that reviews and submits proposals for director and senior management remuneration to the board[165]. - The company emphasizes the importance of performance-based remuneration linked to operational targets[166]. Employee and Talent Management - The company has a total of 5,001 employees, with 2,503 in production, 1,199 in technical roles, and 128 in sales[181]. - The company has implemented a five-year human resources strategic plan to align with its overall business strategy[183]. - The company has committed to providing competitive salaries and benefits to its employees, ensuring compliance with labor laws[182]. - The company will continue to enhance its internal talent system and accelerate the construction of a talent training program to improve the capabilities of key professional talents in marketing, quality, EHS, R&D, and production[140]. Environmental and Social Responsibility - The company invested approximately 23,411.58 million CNY in environmental protection during the reporting period[199]. - The company is classified as a key pollutant discharge unit and has detailed wastewater treatment processes in place[200]. - The company has established an environmental protection mechanism in compliance with regulations[199].

前十大流通股东累计持有： 46253.66万股，累计占流通股比： 51.66%，较上期变化： -2205.34万股。 | 名称 | 持有数量(万股) | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 浙江中贝九洲集团（300040）有限公司 | 28351.88 | 31.67 | 不变 | | 台州市歌德实业有限公司 | 4058.57 | 4.53 | 不变 | | 花莉蓉 | 3190.43 | 3.56 | 不变 | | 中国工商银行股份有限公司-中欧医疗健康混合型证券投 资基金 | 2179.11 | 2.43 | 新进 | | 中国银行股份有限公司-华宝中证医疗交易型开放式指数 | | | | | 证券投资基金 | 1750.25 | 1.96 | 新进 | | 林辉潞 | 1747.67 | 1.95 | 不变 | | 全国社保基金四一八组合 | 1527.08 | 1.71 | -211.09 | | 中国工商银行股份有限公司-中欧医疗创新股票型证券投 | | | | | 资基金 | 1252.77 | 1.40 ...

财报显示，中欧基金旗下2只基金进入九洲药业前十大股东，持股比例为3.46%。其中中欧医疗健康混合A去年四季度增持，中欧医疗创新股票A去年四季度 减持。 其中，中欧医疗健康混合A今年以来收益率4.45%，同类排名1657(总4592)，中欧医疗创新股票A今年以来收益率21.76%，同类排名22(总1001)。 4月7日，九洲药业股票盘中跌停，浙江九洲药业股份有限公司,成立于1998年,总部位于浙江台州,是全球领先的创新药CDMO企业,为全球药企提供创新药临床 前CMC,临床Ⅰ、Ⅱ、Ⅲ期,NDA至商业化上市的一站式的药物研发、生产解决方案和专业服务,树立了国内传统仿制原料药企业转型为创新药CDMO企业的 成功典范。 | 阶段涨幅 | 季度涨幅 年度涨幅 | | ■ 下载 | App6.7.1: | | --- | --- | --- | --- | --- | | | 近1周 | 近1月 | 近3月 | 新功能:"小天 | | 阶段涨幅 | 0.88% | 12.02% | 25.64% | 型，智能问答 | | 同类平均0 | -1.71% | -0.13% | 8.00% | 准、专业的问 | | 沪深300 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603456 证券简称：九洲药业 公告编号：2025-010 一、回购股份的基本情况 浙江九洲药业股份有限公司（以下简称"公司"）于2025年3月21日召开第八届董事会第十二次会议，审 议通过了《关于以集中竞价交易方式回购公司股份的议案》，并于2025年3月22日披露了《浙江九洲药 业股份有限公司关于以集中竞价交易方式回购公司股份的回购报告书》，公司将使用自有资金以集中竞 价交易方式回购公司股份用于后续实施股权激励计划，回购价格不超过人民币20元/股（含），回购资 金总额不低于人民币1亿元（含），不高于人民币2亿元（含），回购期限为自董事会审议通过回购股份 方案之日起12个月内。具体内容详见公司于上海证券交易所网站及《上海证券报》披露的相关公告（公 告编号：2025-006、2025-007）。 浙江九洲药业股份有限公司 关于以集中竞价交易方式回购股份比例达1%的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 二、回购股份的进展情况 根据 ...

证券代码：603456 证券简称：九洲药业 公告编号：2025-010 浙江九洲药业股份有限公司 关于以集中竞价交易方式回购股份比例达 1%的 进展公告 重要内容提示： | 回购方案首次披露日 | 2025/3/22 | | --- | --- | | 回购方案实施期限 | 12 待董事会审议通过后 个月 | | 预计回购金额 | 10,000万元~20,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 305.87万股 | | 累计已回购股数占总股本比例 | 0.34% | | 累计已回购金额 | 4,061.62万元 | | 实际回购价格区间 | 13.00元/股~13.85元/股 | 一、 回购股份的基本情况 浙江九洲药业股份有限公司（以下简称"公司"）于 2025 年 3 月 21 日召开第 八届董事会第十二次会议，审议通过了《关于以集中竞价交易方式回购公司股份 的议案》，并于 2025 年 3 月 22 日披露了《浙江九洲药业股份有限公司关于以集中 竞价交易方式回购公司 ...

证券代码：603456 证券简称：九洲药业 公告编号：2025-009 浙江九洲药业股份有限公司 关于以集中竞价交易方式首次回购股份暨 回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购方案首次披露日 2025/3/22 回购方案实施期限 待董事会审议通过后 12 个月 预计回购金额 10,000 万元~20,000 万元 □减少注册资本 √用于员工持股计划或股权激励 一、 回购股份的基本情况 浙江九洲药业股份有限公司（以下简称"公司"）于 2025 年 3 月 21 日召开第 八届董事会第十二次会议，审议通过了《关于以集中竞价交易方式回购公司股份 ，并于 2025 年 3 月 22 日披露了《浙江九洲药业股份有限公司关于以集中 的议案》 竞价交易方式回购公司股份的回购报告书》，公司将使用自有资金以集中竞价交易 方式回购公司股份用于后续实施股权激励计划，回购价格不超过人民币 20 元/股 （含），回购资金总额不低于人民币 1 亿元（含），不高于人民币 2 亿元（含），回 购期限为自董事会审议通过 ...

证券代码：603456 证券简称：九洲药业 公告编号：2025-009 浙江九洲药业股份有限公司 关于以集中竞价交易方式首次回购股份暨 回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/3/22 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 10,000 万元~20,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 80.33 万股 | | 累计已回购股数占总股本比例 | 0.09% | | 累计已回购金额 | 1,105.79 万元 | | 实际回购价格区间 | 13.68 元/股~13.85 元/股 | 一、 回购股份的基本情况 浙江九洲药业股份有限公司（以下简称"公司"）于 2025 年 3 月 21 日召开第 八届董事会第十二次会议，审议通过了《关于以集 ...

证券代码：603456 证券简称：九洲药业 公告编号：2025-008 浙江九洲药业股份有限公司 关于股份回购事项前十大股东和前十大无限售条件 股东持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江九洲药业股份有限公司（以下简称"公司"）于 2025 年 3 月 21 日召开第 八届董事会第十二次会议，会议审议通过了《关于以集中竞价交易方式回购公司 股份的议案》。具体内容详见公司于 2025 年 3 月 22 日在《上海证券报》和上海 证券交易所网站（www.sse.com.cn）披露的《浙江九洲药业股份有限公司关于以 集中竞价交易方式回购公司股份的回购报告书》（公告编号：2025-007）。 根据《上市公司股份回购规则》、 《上海证券交易所上市公司自律监管指引第 易日（即 2025 年 3 月 21 日）登记在册的前十大股东和前十大无限售条件股东 的名称及持股数量、比例情况公告如下： 一、前十大股东的持股情况 占公司总股 序 持股数量 股东名称 本比例 号 （股） （%） 中国工商银行股份有限公司－中欧医疗 ...

证券代码：603456 证券简称：九洲药业 公告编号：2025-008 浙江九洲药业股份有限公司 关于股份回购事项前十大股东和前十大无限售条件 股东持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、前十大股东的持股情况 | 9 | 中信证券股份有限公司－社保基金 | 17052 | 组合 | 9,891,800 | 1.10 | | --- | --- | --- | --- | --- | --- | | 10 | 何利民 | | | 8,928,560 | 1.00 | 二、前十大无限售条件股东的持股情况 | 序 | | 持股数量 | 占公司总股 | | --- | --- | --- | --- | | 号 | 股东名称 | （股） | 本比例 | | | | | （%） | | 1 | 浙江中贝九洲集团有限公司 | 283,518,812 | 31.67 | | 2 | 台州市歌德实业有限公司 | 40,585,680 | 4.53 | | 3 | 花莉蓉 | 31,904,260 | 3.56 | ...